Compare with Tango Therapeutics, Inc.


Market capitalization
‪3.83 B‬ USDMid cap
−0.84 USD
‪−101.59 M‬ USD
‪62.38 M‬ USD
‪124.15 M‬
Beta (1Y)
0.89
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Employees (FY)
137
Change (1Y)
−18−11.61%
Revenue / Employee (1Y)
‪455.36 K‬ USD
Net income / Employee (1Y)
‪−741.56 K‬ USD

Company info


CEO
Malte Peters
Headquarters
Boston
Founded
2017
IPO date
Sep 3, 2020
ISIN
US87583X1090
CUSIP
87583X109
FIGI
BBG00WFDDRS0
Identifiers
ISIN US87583X1090
CFI code
ESVUFR
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, Antoni Ribas and Barbara Weber in 2017 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Weight0.90%
Market value‪93.68 M‬
Weight0.11%
Market value‪81.16 M‬
Weight0.04%
Market value‪40.83 M‬
Weight0.21%
Market value‪28.75 M‬
Weight0.21%
Market value‪23.64 M‬
Weight0.12%
Market value‪20.43 M‬
Weight0.08%
Market value‪16.76 M‬
Weight0.14%
Market value‪9.45 M‬
Weight0.03%
Market value‪7.11 M‬
Weight0.45%
Market value‪5.27 M‬

Explore more ETFs 

Frequently asked questions


Markets don't sleep, here's what's going on with TNGX at the moment:
– Most and least shorted mid- to mega-cap healthcare stocks at the end of October
– Most shorted stocks on Wall Street
– TNGX Q3'26 Earnings: revenue estimate is 0 USD

See more updates in real-time with our News Flow.
Tango Therapeutics, Inc. is scheduled to release its next earnings report on Nov 10, 2026.

Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release

How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
TNGX stock is 10.10% volatile and has beta coefficient of 0.89.

What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable

Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like TNGX are typically less volatile than smaller companies

Track every detail on Tango Therapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Tango Therapeutics, Inc. there?
To understand the TNGX stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — −4.23%
– 1 week — −7.05%
– 1 month — −13.27%

TNGX all-time low was 1.03 USD (May 8, 2025), and its highest price is 34.39 USD (Jun 17, 2026). Find more dynamics in the Stock Heatmap and on the Tango Therapeutics, Inc. stock chart.
Tango Therapeutics, Inc. market capitalization is ‪3.67 B‬, representing the total value of all its outstanding shares (price × shares outstanding).

What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements

What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Tango Therapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Tango Therapeutics, Inc. stacks up against other companies
The safest way to buy Tango Therapeutics, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.

You can trade TNGX directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 4, 2026, the company has 137 employees.

Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements

See our rating of the largest employers to find more opportunities.
Investing in Tango Therapeutics, Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.

First, study Tango Therapeutics, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency

Then explore our TNGX technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — buy
– 1-month — buy

Combine fundamental and technical analysis for better results.
Tango Therapeutics, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Tango Therapeutics, Inc. stocks trade under the symbol TNGX.

About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners

Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion

Learn how to find your desired assets in our Symbol Search.
TNGX earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.32 USD, resulting in a −16.64% surprise. The estimated earnings for the next quarter are −0.35 USD per share.

How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one

Follow other essential metrics in Tango Therapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Tango Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.

What it might mean:
– Stable demand: Sales are holding steady without clear growth or decline
– Mature business phase: Growth may be slowing in core segments
– Offsetting factors: Strength in some areas may be balancing weakness in others

What to look at next in Tango Therapeutics, Inc. financials:
– Margins: Profitability may improve or decline even if revenue is flat
– Net income & EPS: Cost control or share buybacks can still drive earnings changes
– Segment breakdown: Some business lines may be growing while others shrink
Yes, you can track Tango Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.

Use our Earnings Calendar to never miss important releases and spot opportunities early.
TNGX net income for the last quarter is ‪−55.34 M‬ USD, while the quarter before that showed ‪−45.51 M‬ USD of net income which accounts for −21.59% change.

How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result

Follow other essential metrics in Tango Therapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Tango Therapeutics, Inc. does not currently pay dividends to its shareholders.

Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.

What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
TNGX reached its all-time high of 34.39 USD on Jun 17, 2026. Its all-time low was 1.03 USD and was reached on May 8, 2025.

Explore the Tango Therapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Tango Therapeutics, Inc. EBITDA is ‪−134.42 M‬ USD, with an EBITDA margin of −174.74%.

EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.

What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures

What to look at next in Tango Therapeutics, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 24.00 USD and 69.00 USD for TNGX, based on current estimates.

Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions

Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance